Please ensure Javascript is enabled for purposes of website accessibility

Health Officials Say U.S. Coronavirus Vaccine is Making Good Progress

By Mark Prvulovic - Feb 7, 2020 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of vaccine developer Moderna surged following the announcement.

While China has confirmed that human trials for a coronavirus vaccine are on the way, U.S. health officials have stated that progress on their own, domestic coronavirus vaccine is proceeding along without any hiccups.

National Institute of Allergy and Infectious Disease (NIAID) director Anthony Fauci went on to say that the development of a vaccine is proceeding well. "I'm happy to tell you that there have been no glitches so far," said Fauci. "We will be in people in a Phase 1 trial within the next 2.5 months."

A person holding one vial among dozens, with this one containing the coronavirus.

Image source: Getty Images.

There are now 34,397 confirmed coronavirus cases around the world, with 34,079 of them coming from mainland China. Only 12 of those cases have been diagnosed in the U.S., with the Trump administration having announced mandatory quarantines for people coming from the affected area in China to prevent further outbreaks in the country..

Moderna's stock surges

Moderna (MRNA 0.76%), a biotech company that develops mRNA-based vaccines, has been working alongside the NIAID to develop a treatment for the coronavirus. Funding is provided by a nongovernmental organization known as the Coalition of Epidemic Preparedness Innovations, but at the moment, there isn't a clear compensation structure for Moderna should the drug be successfully developed.

Regardless, investors took this reassurance from the NIAID as a good sign for Moderna, with the company's stock surging by as much as 17%. Other healthcare giants are working to develop their own treatments. Gilead recently made news when its Ebola drug, remdesivir, almost completely eliminated symptoms in a patient it was tested on. The Chinese government is now moving the drug to human trials.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$145.36 (0.76%) $1.09
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.83 (-0.40%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.